Compare Aurobindo Pharma with Lupin - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs LUPIN - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA LUPIN AUROBINDO PHARMA/
LUPIN
 
P/E (TTM) x 11.3 -18.7 - View Chart
P/BV x 1.4 2.1 66.4% View Chart
Dividend Yield % 0.8 1.0 74.1%  

Financials

 AUROBINDO PHARMA   LUPIN
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-21
LUPIN
Mar-21
AUROBINDO PHARMA/
LUPIN
5-Yr Chart
Click to enlarge
High Rs1,0231,122 91.2%   
Low Rs333576 57.9%   
Sales per share (Unadj.) Rs422.8334.2 126.5%  
Earnings per share (Unadj.) Rs92.027.0 340.2%  
Cash flow per share (Unadj.) Rs110.046.6 236.0%  
Dividends per share (Unadj.) Rs4.006.50 61.5%  
Avg Dividend yield %0.60.8 77.0%  
Book value per share (Unadj.) Rs374.3300.1 124.7%  
Shares outstanding (eoy) m585.94453.68 129.2%   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x1.62.5 63.2%   
Avg P/E ratio x7.431.4 23.5%  
P/CF ratio (eoy) x6.218.2 33.9%  
Price / Book Value ratio x1.82.8 64.1%  
Dividend payout %4.324.0 18.1%   
Avg Mkt Cap Rs m397,398385,072 103.2%   
No. of employees `000NANA-   
Total wages/salary Rs m35,35028,259 125.1%   
Avg. sales/employee Rs Th00-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th00-  
INCOME DATA
Net Sales Rs m247,746151,630 163.4%  
Other income Rs m3,8091,363 279.4%   
Total revenues Rs m251,555152,993 164.4%   
Gross profit Rs m81,48025,669 317.4%  
Depreciation Rs m10,5548,874 118.9%   
Interest Rs m7451,406 53.0%   
Profit before tax Rs m73,99016,751 441.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m20,0984,485 448.1%   
Profit after tax Rs m53,89212,266 439.4%  
Gross profit margin %32.916.9 194.3%  
Effective tax rate %27.226.8 101.4%   
Net profit margin %21.88.1 268.9%  
BALANCE SHEET DATA
Current assets Rs m198,235139,864 141.7%   
Current liabilities Rs m106,65284,361 126.4%   
Net working cap to sales %37.036.6 101.0%  
Current ratio x1.91.7 112.1%  
Inventory Days Days1969 27.7%  
Debtors Days Days52108 47.9%  
Net fixed assets Rs m135,77894,439 143.8%   
Share capital Rs m586907 64.6%   
"Free" reserves Rs m218,713135,229 161.7%   
Net worth Rs m219,299136,136 161.1%   
Long term debt Rs m1,684161 1,044.7%   
Total assets Rs m334,013234,302 142.6%  
Interest coverage x100.312.9 777.1%   
Debt to equity ratio x00 648.5%  
Sales to assets ratio x0.70.6 114.6%   
Return on assets %16.45.8 280.3%  
Return on equity %24.69.0 272.7%  
Return on capital %33.813.3 253.9%  
Exports to sales %53.80-   
Imports to sales %16.40-   
Exports (fob) Rs m133,248NA-   
Imports (cif) Rs m40,615NA-   
Fx inflow Rs m133,24851,027 261.1%   
Fx outflow Rs m44,94621,081 213.2%   
Net fx Rs m88,30229,946 294.9%   
CASH FLOW
From Operations Rs m33,28918,218 182.7%  
From Investments Rs m5,987-12,396 -48.3%  
From Financial Activity Rs m-13,648-18,853 72.4%  
Net Cashflow Rs m25,831-13,031 -198.2%  

Share Holding

Indian Promoters % 48.8 46.5 104.9%  
Foreign collaborators % 3.1 0.3 1,096.4%  
Indian inst/Mut Fund % 38.3 41.9 91.5%  
FIIs % 20.8 14.7 142.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 48.2 53.2 90.5%  
Shareholders   338,639 378,547 89.5%  
Pledged promoter(s) holding % 14.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   SUN PHARMA    CIPLA    DR. REDDYS LAB    ZYDUS LIFESCIENCES    PIRAMAL ENTERPRISES    



Today's Market

Sensex Ends 150 Points Lower, Nifty Falls Below 15,800; FMCG & Banking Stocks Witness Selling(Closing)

After opening deep in the red, Indian share markets recovered most of the losses as the session progressed but still ended on a negative note.

Related Views on News

Aurobindo Pharma Rallies on Sale of Injectables Unit to Subsidiary (Views On News)

Jul 2, 2021

Here's why the company sold its business unit to Eugia Pharma Specialities.

5 Takeaways from Sun Pharma's Q4 Results (Views On News)

May 30, 2022

It came as a surprise to everyone when Sun Pharma reported a consolidated net loss in Q4 instead of a profit.

Why Divi's Lab Share Price is Falling (Views On News)

May 24, 2022

Here's why Divi's Lab's stock fell over 10% in two days.

Divi's Lab Net Profit Rises 78%. Company Declares 1,500% Dividend (Views On News)

May 23, 2022

For full year, profit figures stood at Rs 29.6 bn as against Rs 19.8 bn for the previous year, reflecting a growth of 49%.

Dr Reddy's Net Profit Falls 76%. Company Declares 600% Dividend (Views On News)

May 19, 2022

During Q4, there were many changes to the products forming part of Dr Reddy's generics and proprietary products segments.

More Views on News

Most Popular

4 Sectors to Watch for Future Multibagger Stocks(Views On News)

Jun 17, 2022

With India's economic recovery accelerating, these sectors are likely to give multibagger returns in the future.

Best Monopoly Stocks to Own in 2022(Views On News)

Jun 18, 2022

Constant product innovation, latest technology, strong supply chain etc can all help companies enjoy monopoly like fortunes.

Is it Time to Start Buying Stocks Selectively?(Profit Hunter)

Jun 16, 2022

Some sectors have corrected by 50%. Do they merit a look?

The One Smallcap Stock I'll Recommend Now(Profit Hunter)

Jun 21, 2022

This aspect of investing has a very high weightage on your overall returns, but often gets ignored when winning stories are written.

The Greatest Dividend Stock of All Time is...(Views On News)

Jun 16, 2022

Prudent investors should consider dividend aristocrats to create passive, predictable, and growing income to rely on whether the market moves up or down in these uncertain times.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Jun 29, 2022 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 8-QTR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS